As for SCH772984, enhanced effects were reported in response to triple combinations, as in breast cancer cells treated with SCH772984, ABT-737, and HER-2 inhibitors, or in acute myeloid leukemia cells treated with SCH772984, ABT-199, and PI3K/mTOR inhibitors [53,54]. This evidence concerns the gene ERBB2 and acute myeloid leukemia.